x.com· @ · X·· 2026-04-22Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
daraxonrasib ± GnP · mono ORR 47%; +GnP ORR 55%, DCR 90%
Body
Come join us in 15 minutes in Ballroom 6A at #AACR26 to hear about advances in #PancreaticCancer therapies & research!
@DrShubhamPant https://t.co/tsGpem1nFy
Heat 10 · 10 likes · 0 replies · 0 reposts
Source: x.com · x.com